News28/10/2026
Formation Bio announces separate drug development accelerator fund
Formation Bio, Inc. →Formation Bio announced a drug development accelerator fund with [figure hidden] in commitments. It serves as general partner through a wholly owned subsidiary and invests its own capital alongside limited partners. The fund exclusively finances drug programs within the company’s portfolio, with each program housed in a standalone corporate entity. Formation Bio supplies the clinical and operating infrastructure. The announcement separates program economics from those of the parent and describes a target of acquiring 10–15 programs over three to five years, not completed acquisitions. Fund commitments are not reported as parent revenue, cash or AUM.